Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial

Fig. 2

Hypoglycemic rates (events per patient—year) a Mesenchymal stem cell (MSC) transplantation versus placebo, b Early versus late transplantation (Grade I: < lower limit of normal (LLN)—55 mg/dL; Grade II: < 55–40 mg/dL; Grade III: < 40–30 mg/dL; Grade IV: < 30 mg/dL, life-threatening consequences, seizures; Grade V: Death. Error bars represent the standard deviation. *P < 0.05, **P < 0.01, ***P < 0.001)

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512